Giant Cell Tumor of the Talar Neck

2007 ◽  
Vol 97 (3) ◽  
pp. 225-228 ◽  
Author(s):  
Hakan Selek ◽  
Hamza Özer ◽  
Sacit Turanli ◽  
Özlem Erdem
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Clinical Signs ◽  
Cell Tumor ◽  
Giant Cell Tumors ◽  
Radiographic Appearance ◽  
Aneurysmal Bone Cysts ◽  
Tumors Of Bone ◽  
Brown Tumors ◽  
Small Bones

We describe a patient with a giant cell tumor in the talar head and neck of the left foot who was diagnosed as having osteochondritis dissecans and treated with arthroscopic drilling in this same location 3 years earlier. Giant cell tumors can be confused with several conditions, including giant cell reparative granulomas, brown tumors, and aneurysmal bone cysts. Giant cell tumors of bone typically occur in the epiphysis of long bones, including the distal femur and proximal tibia. They are uncommonly found in the small bones of the foot or ankle, and talar involvement is rare. Despite this rarity, the radiographic appearance and clinical signs of talar lesions should be considered in the differential diagnosis of nontraumatic conditions in the foot. (J Am Podiatr Med Assoc 97(3): 225–228, 2007)

p63 Expression in Giant Cell–Containing Lesions of Bone and Soft Tissue

2011 ◽  
Vol 135 (6) ◽  
pp. 776-779 ◽  
Author(s):  
Gustavo de la Roza
Keyword(s):  
Soft Tissue ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Predictive Value ◽  
Cell Tumor ◽  
Bone Cysts ◽  
Giant Cell Tumors ◽  
Aneurysmal Bone Cysts ◽  
Tumors Of Bone ◽  
Pigmented Villonodular

Abstract Context.—Previous studies have demonstrated p63 overexpression in giant cell tumors of bone and advocate its use as a potential diagnostic marker. Although routine histology is often all that is required to diagnose giant cell tumor of bone, immunohistochemistry could prove useful to distinguish it from other benign and malignant giant cell–containing lesions of bone and soft tissue on needle biopsies and unusual clinical settings. Objective.—To assess p63 expression in giant cell–containing lesions of bone and soft tissue. Design.—p63 immunohistochemistry was performed in 23 giant cell tumors of bone, 8 primary aneurysmal bone cysts, 12 chondroblastomas, 4 giant cell reparative granulomas, 4 osteosarcomas, 15 tenosynovial giant cell tumors, 6 nonossifying fibromas, and 4 pigmented villonodular synovitides. Results.—p63 overexpression was identified in 20 of 23 giant cell tumors of bone (86.9%), 5 of 8 primary aneurysmal bone cysts (62.5%), 10 of 12 chondroblastomas (83.3%), 4 of 4 giant cell reparative granulomas (100%), 2 of 4 osteosarcomas (50%), 1 of 15 tenosynovial giant cell tumors (6.6%), 1 of 6 nonossifying fibromas (16.6%), and 1 of 4 pigmented villonodular synovitides (25%). The sensitivity, specificity, positive predictive value, and negative predictive value of p63 immunohistochemistry for the diagnosis of giant cell tumor of bone were 86.95%, 53.36%, 45.45%, and 91.17%, respectively. Conclusions.—This study shows that although p63 is expressed by most giant cell tumors of bone, its lack of specificity limits its use as an immunohistochemical marker in the differential diagnosis of giant cell–containing lesions of bone and soft tissue.

scholarly journals Giant Cell Tumor of Bone in Patients under 16 Years Old: A Single-Institution Case Series

Cancers ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 2585
Author(s):  
Francesca Ambrosi ◽  
Alberto Righi ◽  
Stefania Benini ◽  
Giovanna Magagnoli ◽  
Ilaria Chiaramonte ◽  
...  
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Pediatric Patients ◽  
Case Series ◽  
Gene Mutations ◽  
Cell Tumor ◽  
Control Group ◽  
Giant Cell Tumors ◽  
Aneurysmal Bone Cysts ◽  
Tumors Of Bone

Background: Giant cell tumor of bone is a locally aggressive, rarely metastasizing tumor that accounts for about 5% of bone tumors and generally occurs in patients between 20 and 45 years old. A driver mutation in the histone 3.3 (H3.3) gene H3F3A has been identified in as many as 96% of giant cell tumors of bone. The immunohistochemical expression of H3F3A H3.3 G34 expression was found in 97.8% of cases. In the present study, we describe our series of cases of giant cell tumor of bone in pediatric patients <16 years old. Methods: All cases of giant cell tumor of bone in pediatric patients <16 years old treated in our institute between 1982 and 2018 were reviewed. Immunohistochemistry and/or molecular analysis for H3F3A gene mutations was performed to confirm the diagnosis. A group of aneurysmal bone cysts in patients <16 years old was used as a control group. Results: Fifteen cases were retrieved. A pronounced female predominance (93%) was observed. A pure metaphyseal central location occurs in 2 skeletally immature patients. Conclusions: Giant cell tumor of bone should be distinguished from its mimickers due to differences in prognosis and treatment. Immunohistochemical and molecular detection of H3F3A gene mutation represents a reliable diagnostic tool.

scholarly journals Brown tumor of the iliac crest initially misdiagnosed as a giant cell tumor of the bone

2020 ◽  
Vol 2020 ◽  
Author(s):  
S Hamidi ◽  
S Mottard ◽  
M J Berthiaume ◽  
J Doyon ◽  
M J Bégin ◽  
...  
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Iliac Crest ◽  
Cell Tumor ◽  
Bone Lesions ◽  
Bone Cysts ◽  
Giant Cell Tumors ◽  
Surgical Interventions ◽  
Aneurysmal Bone Cysts ◽  
Brown Tumors

Summary Brown tumors (BTs) are expansile osteolytic lesions complicating severe primary hyperparathyroidism (PHPT). Clinical, radiological and histological features of BTs share many similarities with other giant cell-containing lesions of the bone, which can make their diagnosis challenging. We report the case of a 32-year-old man in whom an aggressive osteolytic lesion of the iliac crest was initially diagnosed as a giant cell tumor by biopsy. The patient was scheduled for surgical curettage, with a course of neoadjuvant denosumab. Routine biochemical workup prior to denosumab administration incidentally revealed high serum calcium levels. The patient was diagnosed with PHPT and a parathyroid adenoma was identified. In light of these findings, histological slices of the iliac lesion were reviewed and diagnosis of a BT was confirmed. Follow-up CT-scans performed 2 and 7 months after parathyroidectomy showed regression and re-ossification of the bone lesion. The aim of this case report is to underline the importance of distinguishing BTs from other giant cell-containing lesions of the bone and to highlight the relevance of measuring serum calcium as part of the initial evaluation of osteolytic bone lesions. This can have a major impact on patients’ management and can prevent unnecessary invasive surgical interventions. Learning points: Although rare, brown tumors should always be considered in the differential diagnosis of osteolytic giant cell-containing bone lesions. Among giant cell-containing lesions of the bone, the main differential diagnoses of brown tumors are giant cell tumors and aneurysmal bone cysts. Clinical, radiological and histological characteristics can be non-discriminating between brown tumors and giant cell tumors. One of the best ways to distinguish these two diagnoses appears to be through biochemical workup. Differentiating brown tumors from giant cell tumors and aneurysmal bone cysts is crucial in order to ensure better patient care and prevent unnecessary morbid surgical interventions.

scholarly journals Correlation between Campanacci’s radiological classification of giant cell tumor of bone and expression of Cyclin D1 and PCNA

2017 ◽  
Vol 7 (1) ◽  
pp. 47
Author(s):  
Eréndira G. Estrada-Villaseñor ◽  
Hidalgo Bravo Alberto ◽  
C. Bandala ◽  
P. De la Garza-Montano ◽  
Reyes Medina Naxieli ◽  
...  
Keyword(s):  
Cyclin D1 ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Descriptive Study ◽  
Cell Tumor ◽  
Giant Cell Tumors ◽  
Radiological Classification ◽  
Tumors Of Bone ◽  
Made In

Giant cell tumor of bone is considered by his behavior a benign but aggressive neoplasm. The objective of our study was to determine if there is a correlation between the Campanacci’s radiological classification of giant cell tumors of bone and the expression by immunohistochemistry of Cyclin D1 and proliferation cell nuclear antibody (PCNA). A retrospective and descriptive study was made. In total, there were 27 cases. All cases showed Cyclin D1 and PCNA positivity. Rho Spearman for Campanacci and Cyclin D1 expression was 0.06 and for Campanacci and PCNA was 0.418. We conclude that there is a positive correlation between PCNA expression in giant cell tumors of Bone and the Campanacci’s radiological classification II and III, butCyclin D1 expression was no related with radiologic features.

Giant Cell Tumor of Talus: T-Construct Method of Bone Grafting

2016 ◽  
Vol 10 (4) ◽  
pp. 364-367 ◽  
Author(s):  
Abhijeet B. Kadam ◽  
Anoop C. Dhamangaonkar
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Frozen Section ◽  
Articular Surface ◽  
Osteolytic Lesion ◽  
Cell Tumor ◽  
Medial Malleolus ◽  
Giant Cell Tumors ◽  
Intralesional Curettage ◽  
Small Bones

Giant cell tumor (GCT) or osteoclastoma is a benign, locally aggressive tumor with a tendency to recur. Giant cell tumors typically occur in the epiphysis of long bones, including the distal femur and proximal tibia. They are uncommonly found in the small bones of the foot or ankle, and involvement of talus is rare. The authors present a case of GCT of the talar body in a 21-year-old man, which was diagnosed radiologically by the presence of a well-defined osteolytic lesion involving more than half of the talar body with thinning of the cortices. An intralesional curettage and chemical cauterization with phenol was done using a medial approach following an osteotomy of the medial malleolus for adequate exposure. Intraoperative frozen section of curetted tissue was sent and was reported as benign GCT. The residual cavity was packed with autologous corticocancellous bone grafts fashioned in a T-construct like manner. A protective cast was applied for a period of 2 months and patient was subsequently gradually mobilized to full weightbearing status. At 2-year follow-up, there was no clinical or radiologically evident signs of recurrence. There was good consolidation of the bone graft in the talus with no signs of collapse of the weightbearing articular surface. Levels of Evidence: Therapeutic, Level IV: Case Study

scholarly journals Giant Cell Tumor of Bone: Documented Progression over 4 Years from Its Origin at the Metaphysis to the Articular Surface

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Colin Burke ◽  
Thomas Link ◽  
Richard J. O’Donnell ◽  
Soo-Jin Cho ◽  
Daria Motamedi
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Subchondral Bone ◽  
Articular Surface ◽  
Cell Tumor ◽  
Bone Plate ◽  
Subchondral Bone Plate ◽  
Giant Cell Tumors ◽  
Exact Location ◽  
Tumors Of Bone

The exact location of origin for giant cell tumors of bone (GCTB) remains controversial, as lesions are not routinely imaged early but rather late when the tumor is large and clinically symptomatic. At the time of diagnosis, GCTB are classically described as lucent, eccentric lesions with nonsclerotic margins, located within the epiphysis to a greater extent than the metaphysis. Here we present a case of a biopsy proven GCTB initially incidentally seen on MRI as a small strictly metaphyseal lesion, which over the course of several years expanded across a closed physis to involve the epiphysis and abut the articular surface/subchondral bone plate.

scholarly journals Case Report: A Rare Huge Giant Cell Tumor of the Proximal Tibia

2021 ◽  
Author(s):  
Bingxin Zheng ◽  
Lingling Sun ◽  
Guojian Qu ◽  
Chongmin Ren ◽  
Peng Yan ◽  
...  
Keyword(s):  
Case Report ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Proximal Tibia ◽  
Cell Tumor ◽  
Borderline Tumor ◽  
Giant Cell Tumors ◽  
Tumors Of Bone ◽  
Patient Prognosis ◽  
Improve Patient

Abstract Background: Giant cell tumor of bone is a common primary borderline bone tumor, while giant cell tumor of bone in the extremities are generally not very large. Because most tumors have already been controlled by some treatments at the time of pain or finding the tumor. Huge giant cell tumors of bone in the limbs are very rare.Case presentation: We describe a case of a huge giant cell tumor of the proximal tibia with 6-year history and not receiving any treatment. It is not until the rupture and bleeding appeared that the patient is referred to the doctor, and amputation is the only treatment.Conclusions: This report suggests that although giant cell tumor of bone is a borderline tumor, early diagnosis and treatment are essential in order to improve patient prognosis.

Giant cell tumor of the intermediate cuneiform. A case report

1992 ◽  
Vol 82 (4) ◽  
pp. 208-211 ◽  
Author(s):  
EC Dunn ◽  
G Mauro ◽  
R Cohen
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Surgical Procedure ◽  
Cell Tumor ◽  
Radiographic Examination ◽  
X Rays ◽  
Giant Cell Tumors ◽  
Tumors Of Bone ◽  
Preserve Function

Although it has yet to be determined which surgical procedure provides the least chance for recurrence, surgical treatment remains the preferred therapy for giant cell tumors of bone. Few cases of giant cell tumor of the tarsus have been reported in the literature, with less than 10 of these cases occurring in the cuneiforms. When the extent of the tumor is questionable, definitive radiologic techniques should be used to aid in the selection of the most appropriate surgical procedure. Follow-up radiographic examination is critical to ensure that the patient remains tumor free. Yearly chest x-rays are recommended to rule out pulmonary metastasis. Although giant cell tumors represent only 5% to 8% of all benign primary osseous neoplasms of the foot, they have the potential to undergo malignant transformation, increasing the morbidity and mortality to the patient. Giant cell tumors of bone are locally aggressive, often occurring adjacent to articular surfaces, and usually are large when diagnosed. It is essential for the surgeon to plan a treatment that not only minimizes the chance of recurrence, but also attempts to preserve function of the involved part.

Intramuscular Tenosynovial Giant Cell Tumor Harboring a Novel CSF1-CD96 Fusion Transcript

2021 ◽  
pp. 106689692110498
Author(s):  
Haider Mejbel ◽  
Gene P. Siegal ◽  
Shi Wei
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Gene Rearrangement ◽  
Fusion Transcript ◽  
Cell Tumor ◽  
Molecular Profile ◽  
Small Subset ◽  
Fusion Partner ◽  
Giant Cell Tumors ◽  
Tenosynovial Giant Cell Tumor

Tenosynovial giant cell tumors typically arise in the synovium of joints, bursae, or tendon sheaths. They may occur in an intra- or extra-articular location and can be divided into localized and diffuse types. The neoplastic nature of the lesion has been supported by a recurrent CSF1 gene rearrangement in a small subset of lesional cells, of which the most common fusion partner is COL6A3. Herein, we report a case of intramuscular localized tenosynovial giant cell tumor harboring a novel CSF1-CD96 fusion transcript, thus expanding the molecular profile of this tumor.

scholarly journals A Case Report of Giant Cell Tumor of Proximal Fibula in Children

2020 ◽  
Vol 4 (1) ◽  
pp. 64-67
Author(s):  
Sushil Adhikari ◽  
Arun Sigdel ◽  
Rajesh Kumar Sah ◽  
Luna Devkota
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Tumor ◽  
Long Bone ◽  
Lytic Lesion ◽  
Radiographic Appearance ◽  
X Ray ◽  
Proximal Fibula ◽  
Aggressive Tumor

Giant cell tumour (GCT) is histopathologically benign tumor of long bone particularly in distal femur and the proximal tibia. It commonly occurs in adults of age 20-40 years but rare in children. GCT is considered to be locally aggressive tumor and tendency of recurrence is higher even after surgery. The clinical features are nonspecific, the principle symptoms are pain, swelling and limiting adjacent joint movements. Diagnosis is based on the radiographic appearance and histopathological findings .In our case X-ray showed ill defined lytic lesion on proximal fibula with cortical thinning and MRI finding revealed expansile lyticlesion in meta-epiphysis of right fibula 16×16×28mm adjacent to growth plate with fluid level. The sclerotic rim appears hypo intense on T1 & hyper intense on T2. Core needle biopsy showed giant cell tumor on proximal fibula. Considering the risk of recurrence wide local excision was done. Management of GCT of proximal fibula in young patient is critical for preventing recurrence and enhancing functional outcomes by saving adjacent anatomical structure. No evidence of local recurrence and metastasis was found in 24 months of follow up.

Sign in / Sign up

Export Citation Format

Share Document